POELLATH advises management of Single Use Support on sale of a majority stake to Novo Holdings
Founded in 2017 in Kufstein, Austria by Johannes Kirchmair and Thomas Wurm, Single Use Support is at the forefront of transforming the production process for advanced pharmaceutical modalities with its equipment and consumables used in the bioprocessing value chain. With a focus on solutions for biological drug substances, cell and gene therapies, and mRNA vaccines, the company’s customers include leading pharma companies, biotech companies and CDMOs. Single Use Support’s products have rapidly gained widespread adoption by enhancing operational efficiency, minimising leakage, and effectively mitigating contamination risks in the pharmaceutical production process.
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S) and manages an investment portfolio with a long-term return perspective.
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.
POELLATH has advised the management in the context of the sale regarding the management participation with the following Munich team:
- Dr. Benedikt Hohaus (partner, lead, management participation, M&A/PE)
- Silke Simmer (counsel, management participation, M&A/PE)
- Ida Süß (associate, management participation, M&A/PE)
